EGFR and neoplasm: Our study explores for the first time the innate immune component triggered by osimertinib in the context of targeting HER3 to treat TKI resistance in NSCLC, generating a rationale for trials aiming to improve anti-tumor immunity in mutant-EGFR/NSCLC patients.